The key near-term catalyst is the NKX019 clinical data at ACR Convergence 2026 (Nov 8-11). Positive efficacy or safety signals could drive the stock, while disappointing data would reinforce the bearish narrative. Monitor cash burn trajectory and any updates on enrollment or dosing expansion.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 6 $1.73entry
- T+1 · 8d ago −8.09%α −10.46% · $1.59
- T+5 · 4d ago −31.21%α −33.81% · $1.19
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Nkarta reported Q3 2026 net loss of $33.3M ($0.45 per share), wider than the $0.38 consensus estimate and the year-ago $0.29 loss. Cash burn continues with $216M remaining, funding operations into 2029. Initial clinical data for NKX019 in myositis and systemic sclerosis will be presented at ACR Convergence 2026, a key catalyst.
Key Financial Metrics
Key Facts
- Net loss of $33.3M ($0.45 per share) for Q3 2026, wider than consensus estimate of $0.38 loss
- Revenue was $0, consistent with pre-revenue clinical-stage biotech
- Cash, cash equivalents, restricted cash, and investments totaled $216.0M as of September 30, 2026, down from $295.1M at year-end 2025
- R&D expenses rose to $29.5M from $20.2M in Q3 2025, a 46% increase
- Initial clinical data for NKX019 in myositis and systemic sclerosis to be presented at ACR Convergence 2026 (Nov 8-11)
- Cash runway expected to fund operations into 2029
Financial Impact
Net loss of $33.3M, EPS miss of $0.07 vs consensus; cash burn of ~$79M in first nine months of 2026
Risk Factors
- Clinical-stage biotech with no approved products or revenue; results from early-stage trials may not be predictive
- Cash burn rate increased 46% YoY in R&D; $216M may not be sufficient if development timelines extend or trials expand
- Competition from other cell therapy developers targeting autoimmune diseases
- Dependence on NKX019 as sole pipeline candidate
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3397171 |
Track record
13 reports on NKTX
4 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +25.75% at T+60 after the Aug 10, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
- Nov 9, 20267d ago Press Release Bullish 7/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
- Nov 6, 202610d ago 8-K Neutral 3/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Bearish 5/10 Viewing Entry $1.73 to $1.59 Now $1.21 +30.06% ▲ +8.09% +10.46% vs SPY
- Aug 10, 202614w ago 8-K Bearish 6/10 Entry $2.33 to $2.39 Now $1.21 +48.07% ▼ −2.58% −2.32% vs SPY
- May 12, 202626w ago Press Release Neutral 4/10 Entry $3.06 to $3.06 Now $1.21 −60.46% · 0.00% +0.00% vs SPY
- Apr 15, 202630w ago Press Release Bullish 7/10 Entry $2.80 to $3.47 Now $1.21 −56.79% ▲ +23.93% +22.71% vs SPY
- Apr 6, 202632w ago EFFECT Bearish 7/10 Entry $2.36 to $2.25 Now $1.21 +48.73% ▲ +4.66% +4.72% vs SPY
- Mar 25, 202633w ago 8-K Bearish 6/10 Entry $2.14 to $2.06 Now $1.21 +43.46% ▲ +3.74% +2.06% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers